Neoadjuvant tislelizumab combination chemotherapy for advanced penile cancer: A case report

Neoadjuvant tislelizumab combination chemotherapy for advanced penile cancer: A case report

Bibliographic Details
Main Authors:	Wei-Chao Dou, Juan Xu, Ji-Yan Liu, Xiang Li
Format:	Article
Language:	English
Published:	Elsevier 2022-03-01
Series:	Asian Journal of Surgery
Subjects:	Neoadjuvant therapy Tislelizumab Chemotherapy Penile cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S1015958421008290

Similar Items

Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort
by: Qi Jiang, et al.
Published: (2023-05-01)

Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study
by: Wenwu He, et al.
Published: (2022-06-01)

Neoadjuvant chemotherapy for patients with locally advanced penile cancer: an updated evidence
by: Xian-Yan-Ling Yi, et al.
Published: (2022-01-01)

Efficacy and Adverse Reaction of Tislelizumab Combined with Chemotherapy on Urothelial Carcinoma
by: WEI Zongjie, et al.
Published: (2022-07-01)

Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): the protocol of a prospective, single-arm, phase II trial
by: Jinsong Yang, et al.
Published: (2023-03-01)

Role of radiotherapy in the treatment of locally advanced penile cancer
by: Mirela Šambić-Penc, et al.
Published: (2022-01-01)

Neoadjuvant docetaxel, cisplatin and ifosfamide (ITP) combination chemotherapy for treating penile squamous cell carcinoma patients with terminal lymph node metastasis
by: Jian Xu, et al.
Published: (2019-06-01)

Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review
by: Nan Zhou, et al.
Published: (2023-02-01)

Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial
by: Yuping Yin, et al.
Published: (2022-08-01)

Perioperative tislelizumab plus chemotherapy for locally advanced resectable thoracic esophageal squamous cell carcinoma trial: a prospective single-arm, phase II study (PILOT trial)
by: Chengzhi Ding, et al.
Published: (2023-12-01)

Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real−world retrospective study
by: Wen-Jie Wu, et al.
Published: (2023-11-01)

Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer
by: Xueyan Liang, et al.
Published: (2023-01-01)

Corrigendum: Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real−world retrospective study
by: Wen-Jie Wu, et al.
Published: (2024-01-01)

RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03)
by: Feng Wen, et al.
Published: (2024-01-01)

Tislelizumab combined with sunitinib in the treatment of metastatic clear cell renal cell carcinoma with renal venous tumor thrombus: A case report and literature review
by: Zhixiang Gao, et al.
Published: (2024-05-01)

Neoadjuvant chemotherapy may be the best neoadjuvant therapy modality for non-metastatic pancreatic cancer: a population based study
by: Jie Yang, et al.
Published: (2024-04-01)

Recent advance in neoadjuvant chemotherapy for rectal cancer
by: GUO Yang, GUO Tian′an, XU Ye
Published: (2022-07-01)

Case report: Gemcitabine intravesical hyperthermic infusion combined with tislelizumab in muscle invasive bladder urothelium carcinoma
by: Zheng Du, et al.
Published: (2022-12-01)

Neoadjuvant chemotherapy for colon cancer
by: M. Yu. Fedyanin, et al.
Published: (2022-06-01)

Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective study
by: Xiang Ren, et al.
Published: (2022-08-01)

A case report: A new promising treatment for pulmonary sarcomatoid carcinoma - Tislelizumab and Anlotinib combined with local radiotherapy
by: Ruoxue Cai, et al.
Published: (2023-11-01)

Complete remission of locally adComplete remission of locally advanced penile squamous cell carcinoma after multimodality treatment
by: Yifan Meng, et al.
Published: (2016-12-01)

Identification of patients with locally advanced rectal cancer eligible for neoadjuvant chemotherapy alone: Results of a retrospective study
by: Yi‐min Han, et al.
Published: (2023-06-01)

Severe thyrotoxicosis induced by tislelizumab: a case report and literature review
by: Liman Huo, et al.
Published: (2023-10-01)

Pharmacological Effects and Clinical Evaluation of PD-1 Inhibitor of Tislelizumab in the Treatment of Advanced Malignant Tumors
by: LUO Xiangchong, et al.
Published: (2022-07-01)

Complete remission in a patient with metastatic gastric cancer receiving tislelizumab combined with chemotherapy: a case report
by: Zhe Zhu, et al.
Published: (2023-05-01)

Case Report: Complete response after tislelizumab treatment in a hepatocellular carcinoma patient with abdominal lymph node metastasis
by: Haihui Deng, et al.
Published: (2023-04-01)

Treatment of Metastatic Primary Extramammary Paget Disease With Combination Anlotinib and Tislelizumab: A Case Report and Review of the Literature
by: Xin Yin, et al.
Published: (2022-05-01)

Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
by: Zhou C, et al.
Published: (2023-11-01)

Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab with or Without Transhepatic Arterial Embolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and High Tumor Burden: A Multicenter Retrospective Study
by: Chen S, et al.
Published: (2023-07-01)

Adrenal insufficiency development during chemotherapy plus anti-programmed death receptor-1 monoclonal antibody (tislelizumab) therapy in patients with advanced gastric cancer: two case reports
by: Jin Ho Baek
Published: (2022-01-01)

Neoadjuvant chemotherapy in the combination treatment for locally advanced rectal cancer: currently available options
by: D. V. Kuzmichev, et al.
Published: (2018-11-01)

Complete remission of gallbladder neuroendocrine carcinoma with liver metastasis by tislelizumab plus chemotherapy: a case report
by: Huafei Li, et al.
Published: (2024-01-01)

Neoadjuvant and Adjuvant Chemotherapy in Osteosarcoma (The Experience of HORC in the Shariati Hospital)
by: Alimoghadam K, et al.
Published: (2004-07-01)

The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer
by: Xia Luo, et al.
Published: (2022-07-01)

Tislelizumab for cervical cancer: A retrospective study and analysis of correlative blood biomarkers
by: Xiaojing Zheng, et al.
Published: (2023-02-01)

Preoperative Concurrent Chemoradiotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: Phase II Randomized Study
by: Xin Wang, et al.
Published: (2022-04-01)

Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China
by: Dongchu Zhou, et al.
Published: (2022-08-01)

Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
by: Fenghao Shi, et al.
Published: (2022-11-01)

Outcomes of neoadjuvant chemotherapy in resectable, borderline resectable and locally advanced pancreatic cancer
by: Kamil D. Dalgatov, et al.
Published: (2021-08-01)